An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
VERDICT
The label
Distribution
read at $31.08
Teva- Pharmaceutical Industries Ltd ADR holds its Distribution at $31.08.
PHPhase · the trend structure carries the Distribution label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-27
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 25 days
Price
$31.08
Valuation
23.19 trailing · 10.05 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.86
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$31.08
23.19 P/E · 10.05 fwd
Our fair value
$50.00
61% discount
Analyst target (avg)
$40.00
+29% to current
Target low $33.00Analyst target rangeTarget high $50.00
▲ current $31.08 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$31.08
you are here
Conservative
$50.00
+61%
Analyst avg
$40.00
+29%
Our fair value
$50.00
+61%
Analyst high
$50.00
+61%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
2.30%
Profit margin
9.02%
Debt to equity
205.60
Analyst consensus
Strong Buy · 10 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✓ PASSES
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows. Against market value it is 45.4%, under the 30% line the market-value standard uses — so that standard clears it.Divergent
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Generics Maker Stuck in Low Gear
Picture a pharmacy shelf where every pill costs less than the branded version yet still earns steady money for the company that makes it. Teva sits at that table, turning out generics across dozens of markets with a 9% profit margin and 22% return on equity. The shares trade at 10.4 times forward earnings, well below our $50 fair value, and the business clears our ethical screen.
We still pass. Revenue growth has settled at just 2%, the moat is rated narrow, and the opportunity rating comes back as None. Analyst targets sit at $40, already reflecting some recovery, but the low single-digit top line leaves little room for sustained outperformance.
The real risk is relentless price pressure on generics plus regulatory and legal overhangs that can swing results quickly. A narrow moat means competitors can copy the same moves. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Israel and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (10 analysts) rates it strong buy, with a mean price target of $41. Entered 2026-07-18 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-18Markdown$34.63+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (10 analysts) rates it strong buy, with a mean price target of $41.
2026-07-03Markdown$34.63+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$34.63Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
POLITICAL
The political ledger · congressional disclosures
Disclosures naming TEVA
Date
Politician
Party
Type
Amount
2026-04-13
Ro Khanna
Democrat
Purchase
1K–15K
15 May2026
Ro Khanna
Democrat
sell
1K–15K
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$35.84
-6.3%
·
$938
-6.3%
2 months
$30.82
+9.0%
·
$1,090
+9.0%
3 months
$29.30
+14.7%
·
$1,147
+14.7%
6 months
$30.18
+11.3%
·
$1,113
+11.3%
1 year
$17.59
+91.0%
·
$1,910
+91.0%
2 years
$16.85
+99.4%
·
$1,994
+99.4%
3 years
$7.33
+358.4%
·
$4,584
+358.4%
5 years
$11.11
+202.4%
·
$3,024
+202.4%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever TEVA does next, these words stay.
Teva- Pharmaceutical Industries Ltd ADR · TEVA · Distribution · $31.08
Recorded 2026-07-27 · before the outcome · scored mechanically
